Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

P. P. Sfikakis; C. Papamichael; K. S. Stamatelopoulos; D. Tousoulis; K. G. Fragiadaki; P. Katsichti; C. Stefanadis; M. Mavrikakis

doi:10.1002/art.22634

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

Arthritis & Rheumatism ◽

10.1002/art.22634 ◽

2007 ◽

Vol 56 (6) ◽

pp. 1985-1993 ◽

Cited By ~ 66

Author(s):

P. P. Sfikakis ◽

C. Papamichael ◽

K. S. Stamatelopoulos ◽

D. Tousoulis ◽

K. G. Fragiadaki ◽

...

Keyword(s):

Systemic Sclerosis ◽

Endothelial Function ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Vascular Endothelial ◽

Endothelin Receptor ◽

Vascular Endothelial Function

Download Full-text

The Nonpeptide Endothelin Receptor Antagonist Bosentan Enhances Myocardial Recovery and Endothelial Function During Reperfusion of the Ischemic Rat Heart

Journal of Cardiovascular Pharmacology ◽

10.1097/00005344-199526003-00131 ◽

1995 ◽

Vol 26 ◽

pp. S445 ◽

Cited By ~ 13

Author(s):

Qing-Dong Wang ◽

Xing-San Li ◽

John Pernow

Keyword(s):

Endothelial Function ◽

Receptor Antagonist ◽

Rat Heart ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Myocardial Recovery

Download Full-text

Protective effect on cardiovascular events of bosentan in clau trial (clinical and endothelial function assessment after endothelin receptor antagonist)

Atherosclerosis ◽

10.1016/j.atherosclerosis.2014.05.244 ◽

2014 ◽

Vol 235 (2) ◽

pp. e92

Author(s):

J. De Haro ◽

S. Bleda ◽

C. Gonzalez-Hidalgo ◽

C. Varela ◽

F. Acin

Keyword(s):

Endothelial Function ◽

Protective Effect ◽

Receptor Antagonist ◽

Cardiovascular Events ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Function Assessment

Download Full-text

The Nonpeptide Endothelin Receptor Antagonist Bosentan Enhances Myocardial Recovery and Endothelial Function During Reperfusion of the Ischemic Rat Heart

Journal of Cardiovascular Pharmacology ◽

10.1097/00005344-199506263-00131 ◽

1995 ◽

Vol 26 ◽

pp. S445 ◽

Cited By ~ 1

Author(s):

Qing-Dong Wang ◽

Xing-San Li ◽

John Pernow

Keyword(s):

Endothelial Function ◽

Receptor Antagonist ◽

Rat Heart ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Myocardial Recovery

Download Full-text

The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial

Diabetologia ◽

10.1007/s00125-011-2415-y ◽

2011 ◽

Vol 55 (3) ◽

pp. 600-607 ◽

Cited By ~ 50

Author(s):

A. Rafnsson ◽

F. Böhm ◽

M. Settergren ◽

A. Gonon ◽

K. Brismar ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Endothelial Function ◽

Receptor Antagonist ◽

Randomised Trial ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor

Download Full-text

Faculty Opinions recommendation of Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.5194958.8511054 ◽

2011 ◽

Author(s):

David Pollock

Keyword(s):

Endothelial Function ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Coronary Endothelial Function ◽

Term Administration ◽

Early Atherosclerosis

Download Full-text

Effect of the endothelin type A–selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: Results of a prospective pilot study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.04.028 ◽

2014 ◽

Vol 71 (2) ◽

pp. 400-401 ◽

Cited By ~ 17

Author(s):

Lorinda Chung ◽

Katharine Ball ◽

Aaliya Yaqub ◽

Bharathi Lingala ◽

David Fiorentino

Keyword(s):

Systemic Sclerosis ◽

Pilot Study ◽

Receptor Antagonist ◽

Type A ◽

Endothelin Receptor Antagonist ◽

Digital Ulcers ◽

Endothelin Receptor ◽

Prospective Pilot Study

Download Full-text

LONG TERM ENDOTHELIN RECEPTOR ANTAGONIST IMPROVES CORONARY ENDOTHELIAL FUNCTION IN PATIENTS WITH EARLY ATHEROSCLEROSIS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(10)61481-7 ◽

2010 ◽

Vol 55 (10) ◽

pp. A158.E1480

Author(s):

Reriani Kaiga Martin ◽

Eugenia Raichlin ◽

Abhiram Prasad ◽

Verghese Mathew ◽

Ryan Lennon ◽

...

Keyword(s):

Endothelial Function ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Coronary Endothelial Function ◽

Early Atherosclerosis

Download Full-text

484 Influence of endothelin receptor antagonist (Bosentan) on right ventricular Tei-index and aortic distensibility in patients with systemic sclerosis and pulmonary hypertension

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(05)80321-2 ◽

2005 ◽

Vol 4 (1) ◽

pp. 115-116

Keyword(s):

Pulmonary Hypertension ◽

Systemic Sclerosis ◽

Right Ventricular ◽

Receptor Antagonist ◽

Aortic Distensibility ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Tei Index

Download Full-text

Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis

Australasian Journal of Dermatology ◽

10.1111/j.1440-0960.2010.00719.x ◽

2010 ◽

Vol 53 (2) ◽

pp. e32-e33 ◽

Cited By ~ 2

Author(s):

Akiko Nishibu ◽

Erika Sakai ◽

Noritaka Oyama ◽

Toshiyuki Yamamoto

Keyword(s):

Systemic Sclerosis ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor

Download Full-text

SAT0463 Initial Therapy with an Endothelin Receptor Antagonist (ERA) is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort (Pharos)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2538 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 828.1-828

Author(s):

M.R. Lammi ◽

L.A. Saketkoo ◽

S.C. Mathai ◽

R.T. Domsic ◽

V. Steen ◽

...

Keyword(s):

Pulmonary Hypertension ◽

Systemic Sclerosis ◽

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Receptor Antagonist ◽

Initial Therapy ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Pulmonary Arterial

Download Full-text